Experimental cholera vaccines were prepared from suspensions of cholera vibrios which were extracted with Genetron-113. These vaccines, when compared with a control preparation which was not treated with Genetron, had a lower nitrogen content and were less toxic for mice but were as effective in protecting mice against infection and in inducing agglutinating and vibriocidal antibody responses in rabbits. This procedure may permit the preparation of cholera vaccines with a higher antigenic content without the corresponding increase in toxic reactions.
Although vaccination of man against cholera has been a common procedure for over seven decades, the actual value of the parenteral administration of a suspension of killed cholera vibrios in preventing this disease has been definitely established only recently. In 1963, the Pakistan-SEATO Cholera Research Laboratory initiated a controlled field trial of cholera vaccine in rural East Pakistan. The results of this study, in which a commercially prepared vaccine with unusually high mouse potency was used, demonstrated a significant reduction in the incidence of diarrhea associated with Vibrio cholerae in the group that received the vaccine (6) .
Because of the severity of the local reactions to the vaccine employed, the dose for those over 12 years of age was reduced from 0.5 to 0.4 ml during the course of the field trial. Laboratory assays of the vaccine revealed that the bacterial content was from three to six times greater than the 8,000 million vibrios per ml usually present in cholera vaccines and that the toxicity for mice was also relatively high (2) .
The present study was undertaken to provide a vaccine with the high level of antigen required for the protection of man, but with a reduced level of toxicity. Since fluorocarbons have been used to remove proteins from pneumococcal cell preparations (5) and to eliminate nonspecific components from viral antigens (4), Genetron-1 13 (trifluorotrichloroethane) was employed in an attempt to extract toxic components from cholera vibrio suspensions without affecting the ability of the material to protect mice or to elicit antibody responses in rabbits.
MATERIALS AND METHODS
Bacterial cultures. The standard vaccine strains of V. cholerae, National Institutes of Health (NIH) 35A3 (Inaba) and NIH 41 (Ogawa), were employed in this study. These strains were maintained in the freeze-dried state at -20 C. Cultures of each of these strains were obtained by streaking a drop of rehydrated organisms onto the surface of Casamino Acids agar plates [Casamino Acids (Difco), 3%; NaCl, 0.85%; agar (Difco), 2%; pH 7.4]. After 18 hr of incubation at 36 C, approximately a dozen typical colonies were removed from the agar and transferred to 300 ml of Casamino Acids broth [Casamino Acids (Difco), 3%; NaCl, 0.85%; pH 7.4]. The inoculated broth was then incubated for 4 to 6 hr at 36 C. A 2-ml amount of this actively growing culture was then spread over the surface of Casamino Acids agar in each of 100 Kolle flasks. After 18 hr of incubation at 36 C, 10 ml of 0.01 M phosphate-buffered physiological saline [pH 7.4 (BPS)] was introduced into each of the Kolle flasks, the bacterial growth was suspended in this fluid, and the harvests from the 100 flasks were collected and pooled. The monovalent harvest pools were then divided into three portions for subsequent treatment.
Treatment of monovalent suspensions. The three portions of each of the monovalent suspensions were treated as follows. (i) To one portion, Formalin was added to a final concentration of 0.25% and the suspension was held at room temperature (22 C) for 2 days, at which time the vibrios were completely inactivated. The suspension was then stored at 4 C until processed further. (ii) An equal volume of BPS was added to the second portion. The diluted suspension was then mixed with 1.5 volumes of Genetron-113 (Allied Chemical Co., New York, N.Y.) in a Waring Blendor (model CB-5) at a low speed. More time was consistently required to obtain a homogeneous blend 334 PREPARATION OF C} with the Inaba suspensions than with the Ogawa suspensions. With 1-liter volumes per blendor cup, 10 min of blending was required for the Inaba suspensions and 7 min was required for the Ogawa. The Genetron-vibrio mixture was then transferred to another container and stored at 22 C. Separation into three phases occurred almost immediately. These consisted of an uppermost aqueous phase (antigenic portion), a middle gelatinous phase, and a bottom Genetron-113 phase (yellow in color). After 24 hr, the uppermost aqueous phase was removed and stored at 4 C until processed further. (iii) Formalin was added to the third portion to a final concentration of 0.25%, and the suspension was held at room temperature (22 C) for 3 hr. The Formalin-treated material was then diluted with an equal volume of BPS containing 0.25%o Formalin, and the diluted suspension was extracted with Genetron-113 as in (ii).
Preparation of vaccines. Divalent vaccine containing Formalin-inactivated vibrios has been previously prepared in this laboratory and used in field trials in man (1). This. Formalin-treated vaccine, which contained 0.70 mg of nitrogen per ml, served as the standard for the vaccines prepared in the current study. On this basis, the new Formalin-treated Inaba and Ogawa preparations were combined to yield a divalent vaccine (vaccine F) containing equal numbers of Inaba and Ogawa serotypes and a total nitrogen content of 0.70 mg/ml. The Genetron-treated Inaba and Ogawa preparations were combined, as were the FormalinGenetron treated Inaba and Ogawa preparations, to form divalent vaccines G and FG, respectively, on the basis of the same volume proportions used in the Formalin-treated vaccine. The three resulting divalent vaccines were then distributed to vials and dried from the frozen state. The fill volume of the Genetrontreated preparations was twice that of the Formalintreated vaccine to compensate for the 1:2 dilution required for the Genetron extraction. For subsequent Toxicity assay. Toxicity of the rehydrated vaccines was measured in 16-to 1 8-g white Swiss mice. Groups of 10 animals were inoculated intraperitoneally with 0.5 ml of dilutions of the vaccines containing graded nitrogen levels. The mice were observed for 7 days and weighed (in groups) on days 1, 2, 3, 4, and 7.
Potency assay. Potency assays in mice were performed by the standard NIH method (7). The protective potency of a vaccine was expressed in terms of ED5o (ml), as calculated by the method of Worcester and Wilson (8) .
Antibody assays. Groups of four to five rabbits were each inoculated subcutaneously with 1.0 ml of a 1:5 dilution of one of the vaccines. After 14 days, the rabbits were bled. The sera were inactivated at 56 C for 30 min and were tested for agglutinating antibodies and for vibriocidal antibodies by the method described by Finkelstein (3 showed that, in the presence of 0.25%0 Formalin alone, the vibrios remained intact and normal in size. After Formalin-Genetron treatment, the organisms appeared intact but were approximately one-third to one-half the size of the vibrios treated with Formalin alone. No intact organisms were detectable in the harvests treated with Genetron alone. The results of nitrogen and opacity determinations on the rehydrated freezedried vaccines (Table 2) show that the total nitrogen and opacity values of vaccines G and FG were lower than those of vaccine F. In addition, when the rehydrated vaccines were centrifuged, the bulk of the nitrogen was found in the supernatant fluid in the case of vaccines G and FG, rather than in the sediment as was the case in vaccine F. This is undoubtedly the result of rupture of the bacterial cells or the leaching out of cellular material during the extraction procedure, as evidenced in the morphological examination of the vibrios. PREPARATION OF CHOLERA VACCINES nitrogen content of the preparation when compared with a control preparation (vaccine F). Accompanying this reduction in total nitrogen content is a reduction in toxicity for mice. The toxicity is reduced even further when the vibrio suspensions are treated with Formalin before the Genetron treatment.
On the other hand, the treatment of cholera vibrio suspensions with Genetron appears to have no adverse effect on the protective potency of the preparations, as measured in mice, or on the antigenicity of the vibrios, as measured by the production of agglutinating and vibriocidal antibodies in rabbits.
It appears, therefore, that treatment of cholera vibrio suspensions with Formalin and Genetron-113 is an effective method for reducing the toxicity of cholera vaccines, possibly permitting the use of vaccines with a higher antigen content. This may be a means of inducing a greater or longer lasting immunity in man.
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